| Literature DB >> 32887336 |
Sen Guo1,2, Haoan Zhao1,3, Zhongxiao Ma3, Shanshan Zhang2, Mingrou Li1, Zhaojing Zheng1, Xiameng Ren1, Chi-Tang Ho4, Naisheng Bai1.
Abstract
Previously we conducted a phytochemical study on the seeds of Fraxinus excelsior and isolated nine secoiridoid compounds with adipocyte differentiation inhibitory activity and peroxisome proliferator activated receptor alpha (PPARα) activation effects. However, the bioactive constituents and functions of Fraxinus mandshurica seeds have not been studied. In the present study, we investigated the secoiridoid compounds in F. mandshurica seed extract (FM) using column chromatography, 1H-NMR, 13C-NMR and HPLC-DAD methods. The pancreatic lipase inhibitory activities of isolated compounds were evaluated in vitro. Additionally, the anti-obesity and gut microbiota modulation effect of FM on high-fat diet-induced obesity in C57BL/6 mice were also studied in vivo. The results showed that 19 secoiridoids were isolated from FM and identified. The total content of secoiridoids in FM reached 181.35 mg/g and the highest content was nuzhenide (88.21 mg/g). All these secoiridoid compounds exhibited good pancreatic lipase inhibitory activity with inhibition rate ranged from 33.77% to 70.25% at the concentration of 100 μM. After obese mice were administrated with FM at 400 mg/kg.bw for 8 weeks, body weight was decreased by 15.81%. Moreover, FM could attenuate the lipid accumulation in serum and liver, relieve the damage in liver and kidney, and extenuate oxidative stress injury and inflammation caused by obesity in mice. FM could also modulate the structural alteration of gut microbiota in obese mice, increasing the proportion of anti-obesity gut microbiota (Bacteroidetes, Bacteroidia, S24-7 and Allobaculum), and reducing the proportion of obesogenic gut microbiota (Firmicutes and Dorea). This study suggests that F. mandshurica seeds or their secoiridoids may have potential for use as a dietary supplement for obesity management.Entities:
Keywords: Fraxinus mandshurica seed; anti-obesity; gut microbiota; pancreatic lipase; secoiridoids
Mesh:
Substances:
Year: 2020 PMID: 32887336 PMCID: PMC7504722 DOI: 10.3390/molecules25174001
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of secoiridoids in F. mandshurica seeds.
Contents and pancreatic lipase inhibitory activity of secoiridoids.
| No. | Name | Calibration Curves a | R2 | Content b | Inhibition% b | IC50 b |
|---|---|---|---|---|---|---|
|
| GI3 | Y = 481.08 + 6.30X | 0.9984 | 9.17 ± 0.05 | 53.42 ± 6.33 | 95.36 ± 3.12 |
|
| Nuzhenide | Y = 667.40 + 4.41X | 0.9999 | 88.21 ± 0.19 | 43.45 ± 3.28 | 120.97 ± 4.94 |
|
| Ligstroside | Y = 40.34 + 13.69X | 0.9986 | 16.88 ± 0.11 | 49.67 ± 4.25 | 100.59 ± 2.74 |
|
| Oleoside-11-methyl ester | Y = 153.23 + 3.97X | 0.9991 | 2.90 ± 0.03 | 48.53 ± 5.13 | 102.94 ± 4.13 |
|
| Oleuricine A | Y = 32.99 + 2.35X | 0.9997 | 0.42 ± 0.01 | 41.41 ± 1.95 | 126.27 ± 0.87 |
|
| Nicotiflorine | Y = −65.95 + 4.79X | 0.9999 | 7.37 ± 0.10 | 37.35 ± 6.34 | 135.84 ± 4.98 |
|
| Jaspolyanoside | Y = 108.89 + 0.36X | 0.9995 | 3.19 ± 0.02 | 62.41 ± 3.98 | 66.46 ± 2.20 |
|
| Oleopolynuzhenide A | Y = 42.78 + 2.25X | 1.0000 | 0.62 ± 0.03 | 70.25 ± 4.56 | 54.60 ± 2.38 |
|
| Safghanoside G | Y = 91.52 + 2.39X | 1.0000 | 5.55 ± 0.09 | 60.16 ± 5.78 | 67.91 ± 3.49 |
|
| Excelside B | Y = 169.19 + 2.31X | 0.9999 | 3.22 ± 0.02 | 49.98 ± 4.33 | 100.06 ± 2.26 |
|
| Isooleonuezhenide | Y = 81.21 + 3.72X | 0.9999 | 0.89 ± 0.12 | 57.62 ± 4.83 | 90.48 ± 3.67 |
|
| Lucidumoside A | Y = 261.83 + 3.66X | 0.9997 | 6.11 ± 0.01 | 47.69 ± 8.36 | 102.37 ± 5.02 |
|
| Safghanoside A | Y = 130.90 + 1.87X | 0.9996 | 4.81 ± 0.10 | 33.77 ± 6.14 | 193.81 ± 4.60 |
|
| Jaspolyoleoside B | Y = −1.75 + 0.09X | 0.9999 | 1.33 ± 0.05 | 53.32 ± 7.31 | 96.27 ± 4.91 |
|
| 10-hydroxoleoside-7,11-dimethyl ester | Y = −1578.72 + 15.65X | 0.9993 | 5.31 ± 0.01 | 43.57 ± 3.09 | 117.42 ± 1.38 |
|
| GI5 | Y = −2.04 + 1.72X | 0.9999 | 8.91 ± 0.01 | 58.77 ± 6.01 | 90.51 ± 2.24 |
|
| Oleoside-7,11-dimethyl ester | Y = −26.33 + 15.08X | 0.9998 | 10.79 ± 0.02 | 50.11 ± 5.97 | 99.78 ± 3.88 |
|
| Isolignstroside | Y = 235.57 + 4.07X | 0.9999 | 0.22 ± 0.03 | 52.07 ± 2.99 | 98.87 ± 2.85 |
|
| 10-hydroxyligstroside | Y = 6236.70 + 1.94X | 0.9991 | 5.45 ± 0.01 | 36.35 ± 5.27 | 167.72 ± 3.51 |
|
| Orlistat | / | / | / | 73.11 ± 3.23 | 48.92 ± 2.44 |
|
| FM | / | / | / | 80.29 ± 1.28 |
a Y is the value of peak area, X is the value of the compound’s concentration (μg/mL). b Data are represented as the mean ± SD (n = 3).
Figure 2Effects of FM on body weight (A), TC, TG, LDL-C and HDL-C levels in serum (B) and TC, TG and LDL-C levels in liver (C). * p < 0.05 vs. control group. + p < 0.05 vs. model group.
Figure 3Effects of FM on serum ALT and AST activities (A), hepatic MDA content (B), CAT activity (C), SOD activity (D), GSH (E) and NO (F) contents. * p < 0.05 vs. control group. +p < 0.05 vs. model group.
Figure 4Effects of FM on serum IL-6 (A), TNF-α (B) and PGE2 (C) contents. * p < 0.05 vs. control group. + p < 0.05 vs. model group. Pathological sections of liver tissue (D) and epididymal adipose (E) in mice (H&E staining × 200).
Figure 5Effects of FM on serum Cr (A), BUN (B) and UA (C) levels. * p < 0.05 vs. control group.
Figure 6Sequence number and length of samples (A), Venn diagram for describing the common and unique OTUs (B) and rarefaction curve of OTUs of samples (C).
Figure 7The NMDS analysis (A), the relative abundance (%) of bacterial at phylum level in different groups (B), the significantly different species in three groups (C) and the relative abundance the of gut microbial biomarkers in three groups (D).